4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Adagene Inc. (ADAG) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 128 employees. Its market capitalization is roughly $211 million. In the fiscal year ended 2025-12-31, ADAG reported $8M in revenue and ($18M) in net income.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Interactive charts & full statements → Open the ADAG valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $8M | $0M | $18M | $9M | — |
| Operating Income (EBIT) | ($21M) | ($36M) | ($24M) | ($84M) | — |
| Net Income | ($18M) | ($33M) | ($19M) | ($80M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $78M | $89M | $116M | $152M | — |
| Total Liabilities | $43M | $39M | $45M | $69M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ADAG viewer.
About TickerBase · Data methodology & sources